AR118836A1 - Moduladores de la vía de tensión integrada - Google Patents

Moduladores de la vía de tensión integrada

Info

Publication number
AR118836A1
AR118836A1 ARP200101239A ARP200101239A AR118836A1 AR 118836 A1 AR118836 A1 AR 118836A1 AR P200101239 A ARP200101239 A AR P200101239A AR P200101239 A ARP200101239 A AR P200101239A AR 118836 A1 AR118836 A1 AR 118836A1
Authority
AR
Argentina
Prior art keywords
alkyl
membered
halo
optionally substituted
nrbrc
Prior art date
Application number
ARP200101239A
Other languages
English (en)
Inventor
Hanae Benelkebir
John T Randolph
Michael J Dart
Kathleen J Murauski
Lei Shi
Qingwei Zhang
Seungwon Chung
Xiangdong Xu
Yunsong Tong
Jennifer M Frost
Carmela Sidrauski
Kathleen Ann Martin
Original Assignee
Calico Life Sciences Llc
Abbvie Inc
Sygnature Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calico Life Sciences Llc, Abbvie Inc, Sygnature Discovery Ltd filed Critical Calico Life Sciences Llc
Publication of AR118836A1 publication Critical patent/AR118836A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporcionan en la presente compuestos, composiciones y métodos útiles para modular la respuesta de tensión integrada (ISR) y para tratar enfermedades, trastornos y afecciones relacionadas. Reivindicación 1: Un compuesto de la fórmula (1) o una sal, solvato, hidrato, tautómero, N-óxido o estereoisómero farmacéuticamente aceptable de este, donde: D es un cicloalquilo bicíclico puenteado, heterociclilo bicíclico puenteado o cubanilo, donde cada cicloalquilo bicíclico puenteado, heterociclilo bicíclico puenteado o cubanilo está opcionalmente sustituido en uno o más carbonos disponibles con 1 a 4 RX; y donde si el heterociclilo bicíclico puenteado contiene un resto de nitrógeno sustituible, el nitrógeno sustituible puede estar opcionalmente sustituido por RN¹; L¹ es un enlace, alquileno C₁₋₆, heteroalquileno de 2 a 7 miembros, -NRN²- o -O-, donde alquileno C₁₋₆ o heteroalquileno de 2 a 7 miembros está opcionalmente sustituido por 1 - 5 RL¹; L² es un enlace, alquileno C₁₋₆ o heteroalquileno de 2 a 7 miembros, donde alquileno C₁₋₆ o heteroalquileno de 2 a 7 miembros está opcionalmente sustituido por 1 a 5 RL²; R¹ es hidrógeno o alquilo C₁₋₆; R² es hidrógeno o alquilo C₁₋₆; W es un resto de anillo bicíclico fusionado, parcialmente insaturado, de 8 a 10 miembros que comprende un heterociclilo de 5 a 6 miembros fusionado a un fenilo o heteroarilo de 5 a 6 miembros; donde el heterociclilo puede estar opcionalmente sustituido en uno o más carbonos disponibles con 1 a 4 RW¹ y donde el fenilo o heteroarilo puede estar opcionalmente sustituido en uno o más carbonos insaturados disponibles con 1 a 4 RW² y donde, si el heterociclilo contiene un resto de nitrógeno sustituible, el nitrógeno sustituible puede estar opcionalmente sustituido por RN³; A es fenilo o heteroarilo de 5 a 6 miembros, donde fenilo o heteroarilo de 5 a 6 miembros está opcionalmente sustituido en uno o más carbonos disponibles con 1 a 5 RY y donde, si el heteroarilo de 5 a 6 miembros contiene un resto de nitrógeno sustituible, el nitrógeno sustituible puede estar opcionalmente sustituido por RN⁴; cada RL¹ se selecciona independientemente del grupo que consiste en hidrógeno, alquilo C₁₋₆, hidroxi-alquilo C₁₋₆, halo-alquilo C₁₋₆, amino-alquilo C₁₋₆, ciano-alquilo C₁₋₆, oxo, halo, ciano, -ORA, -NRBRC, -NRBC(O)RD, -C(O)NRBRC, -C(O)RD, -C(O)OH, -C(O)ORD, -SRE, -S(O)RD y -S(O)₂RD; cada RL² se selecciona independientemente del grupo que consiste en hidrógeno, alquilo C₁₋₆, hidroxi-alquilo C₁₋₆, halo-alquilo C₁₋₆, amino-alquilo C₁₋₆, ciano-alquilo C₁₋₆, oxo, halo, ciano, -ORA, -NRBRC, -NRBC(O)RD, -C(O)NRBRC, -C(O)RD, -C(O)OH, -C(O)ORD, -SRE, -S(O)RD y -S(O)₂RD; RN¹ se selecciona del grupo que consiste en hidrógeno, alquilo C₁₋₆, hidroxi-alquilo C₂₋₆, halo-alquilo C₂₋₆, amino-alquilo C₂₋₆, ciano-alquilo C₂₋₆, -C(O)NRBRC, -C(O)RD, -C(O)ORD y -S(O)₂RD; RN² se selecciona del grupo que consiste en hidrógeno, alquilo C₁₋₆, hidroxi-alquilo C₂₋₆, halo-alquilo C₂₋₆, amino-alquilo C₂₋₆, ciano-alquilo C₂₋₆, -C(O)NRBRC, -C(O)RD, -C(O)ORD y -S(O)₂RD; RN³ se selecciona del grupo que consiste en hidrógeno, alquilo C₁₋₆, hidroxi-alquilo C₂₋₆, alquil C₁₋₆-cicloalquilo C₁₋₆, alquenilo C₁₋₆, -C(O)-alquilo C₁₋₆, -C(O)-cicloalquilo C₁₋₆, alquilo C₁₋₆-CO₂H, alquil C₁₋₆-CO₂-alquilo C₁₋₆, -C(O)-alquil C₁₋₃-O-alquil C₁₋₃-O-alquilo C₁₋₃, -C(O)-fenilo, -C(O)-heteroarilo, -C(O)-heterociclilo, -S-alquilo C₁₋₆, -S(O)₂-alquilo C₁₋₆, -S(O)₂-fenilo, -S(O)₂-heteroarilo, -C(O)NRBRC y -C(O)ORD; donde alquilo C₁₋₆, hidroxi-alquilo C₂₋₆, alquil C₁₋₆-cicloalquilo C₁₋₆, alquenilo C₁₋₆, C(O)-alquilo C₁₋₆, -C(O)-cicloalquilo C₁₋₆, alquilo C₁₋₆-CO₂H, alquil C₁₋₆-CO₂-alquilo C₁₋₆, -C(O)-heterociclilo, -S-alquilo C₁₋₆ y -S(O)₂-alquilo C₁₋₆ pueden estar opcionalmente sustituidos por uno o más sustituyentes que cada uno se selecciona independientemente del grupo que consiste fluoro, hidroxilo, alcoxi C₁₋₆, alquilo C₁₋₆ (opcionalmente sustituido por uno, dos o tres átomos de fluoro) y S(O)ʷ-alquilo C₁₋₆ (donde w es 0, 1 ó 2); y donde -C(O)-fenilo, -C(O)-heteroarilo, -S(O)₂-fenilo y -S(O)₂-heteroarilo pueden estar opcionalmente sustituidos por uno o más sustituyentes que cada uno se selecciona independientemente del grupo que consiste en halógeno, hidroxilo, alquilo C₁₋₆ (opcionalmente sustituido por uno, dos o tres átomos de flúor), alcoxi C₁₋₆ (opcionalmente sustituido por uno, dos o tres átomos de flúor), S(O₂)NRBRC y SO₂F; RN⁴ se selecciona del grupo que consiste en hidrógeno, alquilo C₁₋₆, hidroxi-alquilo C₂₋₆, halo-alquilo C₂₋₆, amino-alquilo C₂₋₆, ciano-alquilo C₂₋₆, cicloalquilo C₃₋₆, fenilo, heteroarilo de 5 a 6 miembros, -C(O)NRBRC, -C(O)RD, -C(O)ORD y -S(O)₂RD; donde cicloalquilo C₃₋₆, fenilo y heteroarilo de 5 a 6 miembros pueden estar opcionalmente sustituidos por uno o más sustituyentes que cada uno se selecciona independientemente del grupo que consiste en halo, alquilo C₁₋₆ (opcionalmente sustituido por uno, dos o tres átomos de flúor), y alcoxi C₁₋₆ (opcionalmente sustituido por uno, dos o tres átomos de flúor); cada RW¹ se selecciona independientemente del grupo que consiste en hidrógeno, alquilo C₁₋₆ (opcionalmente sustituido por -CO₂H), hidroxi-alquilo C₁₋₆, hidroxi-alquilo C₂₋₆-O-, halo-alquilo C₁₋₆, amino-alquilo C₁₋₆, ciano-alquilo C₁₋₆, oxo, C=NOH, halo, ciano, -ORA, -NRBRC, -NRBRCC, -NRBC(O)RD, -C(O)NRBRC, -C(O)RD, -C(O)OH, -C(O)ORD, -SRE, -S(O)RD y -S(O)₂RD; cada RW² se selecciona independientemente del grupo que consiste en hidrógeno, alquilo C₁₋₆, hidroxi-alquilo C₁₋₆, hidroxi-alquilo C₂₋₆-O-, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, amino-alquilo C₁₋₆, ciano-alquilo C₁₋₆, halo, ciano, -ORA, -NRBRC, -NRBC(O)RD, -C(O)NRBRC, -C(O)RD, -C(O)OH, -C(O)ORD, -S(RF)ₘ, -S(O)RD y -S(O)₂RD; o 2 grupos RW² en átomos adyacentes, junto con los átomos a los que se unen, forman un cicloalquilo fusionado de 3 a 7 miembros, heterociclilo fusionado de 3 a 7 miembros, arilo fusionado o heteroarilo fusionado de 5 a 6 miembros, cada uno de los cuales está opcionalmente sustituido por 1 a 5 RX; cada RX se selecciona independientemente del grupo que consiste en hidrógeno, alquilo C₁₋₆, hidroxi-alquilo C₁₋₆, halo-alquilo C₁₋₆, amino-alquilo C₁₋₆, ciano-alquilo C₁₋₆, oxo, halo, ciano, -ORA, -NRBRC, -NRBC(O)RD, -C(O)NRBRC, -C(O)RD, -C(O)OH, -C(O)ORD, -SRE, -S(O)RD y -S(O)₂RD; cada RY se selecciona independientemente del grupo que consiste en hidrógeno, alquilo C₁₋₆, hidroxi-alquilo C₁₋₆, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, amino-alquilo C₁₋₆, ciano-alquilo C₁₋₆, cicloalquilo C₃₋₆, heterociclilo de 3 a 7 miembros, halo-alquilo C₁₋₆ de 3 a 7 miembros, halo, ciano, -ORA, -NRBRC, -NRBC(O)RD, -C(O)NRBRC, -C(O)RD, -C(O)OH, -C(O)ORD, -S(RF)ₘ, -S(O)RD, -S(O)₂RD y G¹; o 2 grupos RY en átomos adyacentes, junto con los átomos a los que se unen, forman un cicloalquilo fusionado de 3 a 7 miembros, heterociclilo fusionado de 3 a 7 miembros, arilo fusionado o heteroarilo fusionado de 5 a 6 miembros, cada uno de los cuales está opcionalmente sustituido por 1 a 5 RX; cada G¹ es independientemente cicloalquilo de 3 a 7 miembros, heterociclilo de 3 a 7 miembros, arilo o heteroarilo de 5 a 6 miembros, donde cada cicloalquilo de 3 a 7 miembros, heterociclilo de 3 a 7 miembros, arilo o heteroarilo de 5 a 6 miembros está opcionalmente sustituido por 1 a 3 RZ; cada RZ se selecciona independientemente del grupo que consiste en alquilo C₁₋₆, hidroxi-alquilo C₁₋₆, halo-alquilo C₁₋₆, halo, ciano, -ORA, -NRBRC, -NRBC(O)RD, -C(O)NRBRC, -C(O)RD, -C(O)OH, -C(O)ORD y -S(O)₂RD; RA es, en cada caso, independientemente hidrógeno, alquilo C₁₋₆, halo-alquilo C₁₋₆, -C(O)NRBRC, -C(O)RD o -C(O)ORD; cada uno de RB y RC es independientemente hidrógeno o alquilo C₁₋₆; RB y RC junto con el átomo al que se unen forman un anillo heterociclilo de 3 a 7 miembros opcionalmente sustituido por 1 a 3 RZ; cada RCC se selecciona independientemente del grupo que consiste en hidroxi-alquilo C₁₋₆, halo-alquilo C₁₋₆, alquilo C₁₋₆-CO₂H, alquil C₁₋₆-CO₂-alquilo C₁₋₆, C(O) alquilo C₁₋₆, S(O)₂-alquilo C₁₋₆, cicloalquilo de 3 a 6 miembros y heterociclilo de 4 a 6-miembros; donde cicloalquilo de 3 a 6 miembros y heterociclilo de 4 a 6 miembros pueden estar opcionalmente sustituidos por uno o más sustituyentes que cada uno se selecciona independientemente del grupo que consiste en alquilo C₁₋₆, hidroxi-alquilo C₁₋₆, haloalquilo C₁₋₆, hidroxilo, halo y -C(O)OH; cada RD es independientemente alquilo C₁₋₆ o haloalquilo-C₁₋₆; cada RE es independientemente hidrógeno alquilo C₁₋₆ o halo-alquilo C₁₋₆; cada RF es independientemente hidrógeno, alquilo C₁₋₆ o halo; y m es 1 cuando RF es hidrógeno o alquilo C₁₋₆, o 5 cuando RF es halo.
ARP200101239A 2019-04-30 2020-04-30 Moduladores de la vía de tensión integrada AR118836A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962840945P 2019-04-30 2019-04-30

Publications (1)

Publication Number Publication Date
AR118836A1 true AR118836A1 (es) 2021-11-03

Family

ID=71465400

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101239A AR118836A1 (es) 2019-04-30 2020-04-30 Moduladores de la vía de tensión integrada

Country Status (15)

Country Link
US (2) US20210363136A1 (es)
EP (1) EP3962899A1 (es)
JP (1) JP2022530647A (es)
KR (1) KR20220016467A (es)
CN (1) CN114401952A (es)
AR (1) AR118836A1 (es)
AU (1) AU2020266592A1 (es)
BR (1) BR112021021754A2 (es)
CA (1) CA3138144A1 (es)
IL (1) IL287660A (es)
MX (1) MX2021013193A (es)
SG (1) SG11202111970WA (es)
TW (1) TW202106671A (es)
UY (1) UY38685A (es)
WO (1) WO2020223536A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530446A (ja) 2017-08-09 2020-10-22 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 化合物、組成物、及び、方法
BR112020008834A2 (pt) 2017-11-02 2020-12-22 Calico Life Sciences Llc Moduladores da via de estresse integrada
EP3723762A4 (en) 2017-12-13 2021-12-08 Praxis Biotech LLC STRESS INTEGRATED RESPONSE PATH INHIBITORS
MX2020013269A (es) 2018-06-05 2021-02-18 Praxis Biotech LLC Inhibidores de la vía de respuesta al estrés integrada.
TWI832295B (zh) 2018-10-11 2024-02-11 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
MX2021009669A (es) 2019-02-13 2021-10-13 Denali Therapeutics Inc Compuestos, composiciones y métodos.
WO2020252207A1 (en) 2019-06-12 2020-12-17 Praxis Biotech LLC Modulators of integrated stress response pathway
MX2022011143A (es) 2020-03-11 2022-10-13 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
US20230391725A1 (en) 2020-10-22 2023-12-07 Evotec International Gmbh Modulators of the integrated stress response pathway
IL302219A (en) 2020-10-22 2023-06-01 Evotec Int Gmbh Integrated stress response pathway modulators
WO2022084448A1 (en) 2020-10-22 2022-04-28 Evotec International Gmbh Modulators of the integrated stress response pathway
PE20240415A1 (es) * 2020-10-30 2024-03-05 Abbvie Inc Moduladores de la via integrada del estres
WO2023119320A1 (en) * 2021-12-25 2023-06-29 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) A preparation of quinazolinediones and use thereof
CN114839296B (zh) * 2022-05-13 2023-12-22 普研（上海）标准技术服务有限公司 食品中牛肉酮的检测方法
CN116768877A (zh) * 2022-05-30 2023-09-19 中国药科大学 Isr抑制剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201808888A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
WO2018225093A1 (en) * 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
UY37958A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37957A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EP3768660A1 (en) * 2018-03-23 2021-01-27 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2

Also Published As

Publication number Publication date
WO2020223536A1 (en) 2020-11-05
IL287660A (en) 2021-12-01
AU2020266592A1 (en) 2021-12-02
CA3138144A1 (en) 2020-11-05
EP3962899A1 (en) 2022-03-09
CN114401952A (zh) 2022-04-26
KR20220016467A (ko) 2022-02-09
TW202106671A (zh) 2021-02-16
BR112021021754A2 (pt) 2022-02-08
US20210363136A1 (en) 2021-11-25
JP2022530647A (ja) 2022-06-30
UY38685A (es) 2020-11-30
MX2021013193A (es) 2022-02-22
SG11202111970WA (en) 2021-11-29
US20240018133A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
AR118836A1 (es) Moduladores de la vía de tensión integrada
AR118837A1 (es) Moduladores de la vía integrada del estrés
AR108394A1 (es) Moduladores de la vía de estrés integrada
AR110599A1 (es) Moduladores de la vía de estrés integrada
AR108395A1 (es) Moduladores de la vía de estrés integrada
AR115993A2 (es) Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
AR113820A1 (es) Compuestos bicíclicos en puente como moduladores del receptor farnesoide x
AR113929A1 (es) Compuestos heterocíclicos
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR117978A1 (es) Inhibidores de 15-pgdh
AR098721A1 (es) Inhibidores de biarilo de tirosina quinasa de bruton
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR100713A1 (es) Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
ES2571741T3 (es) Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa
AR101222A1 (es) Derivados de piridona
AR122407A1 (es) Composiciones y métodos para tratar la inflamación intestinal usando un inhibidor de ccr9 y anticuerpos de bloqueo anti-il-23
AR113824A1 (es) Moduladores de la vía de estrés integrada
AR123974A1 (es) Moduladores de la vía integrada del estrés
ES2667276T3 (es) Derivados de sulfonilindol y método para prepararlos
AR108671A1 (es) Análogos de diamida imidodicarbonimidica
AR114188A1 (es) Moduladores de la vía de estrés integrada
AR113825A1 (es) Moduladores de la vía de estrés integrada
AR121840A1 (es) Compuestos herbicidas
AR105097A1 (es) Antiparasitarios de carbolina
AR102220A1 (es) Imidazopiridinas e imidazopirazinas como inhibidores de lsd1